Hemorrhagic Disorders
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents

https://doi.org/10.1111/j.1538-7836.2009.03429.xGet rights and content
Under an Elsevier user license
open archive

Summary

Heparin, low molecular weight heparin (LMWH) and coumarins are familiar to most clinicians, inexpensive, highly effective when correctly used and widely available. However, coumarin has a delayed onset of action, interacts with many medications, has a narrow therapeutic window, and can cause thrombosis in some settings (e.g. hereditary protein C deficiency, heparin induced thrombocytopenia, warfarin loading). Additionally, warfarin and heparin require monitoring of their therapeutic effect. These real and perceived limitations have led to the development of ‘novel’ anticoagulants. However, these new agents have one general limitation – a lack of a widely available antidote. We focus on the management of bleeding in anticoagulated patients, with particular regard to novel anticoagulants.

Keywords

clinical trials
hemorrhage
management
review

Cited by (0)